Back to Selank research
selank anxiolytic preclinical animal n preclinical 2026-04-03 PubMed

Selank and Its Fragments Modulate Immune Gene Expression in Mice

[Changes in expression of the genes for chemokines, cytokines, and their receptors in response to selank and its fragments].

Background

Selank, a synthetic analog of taftsin, is known for its anxiolytic (anti-anxiety) and nootropic (cognitive-enhancing) effects, alongside pronounced antiviral properties. Despite its diverse pharmacological profile, the precise mechanisms underlying its immunomodulatory actions, particularly at the genetic level, were not fully elucidated. This study aimed to investigate how Selank and its fragments influence the expression of genes related to chemokines, cytokines, and their receptors in mouse spleen.

Results

The study revealed that both Selank and its fragments induced significant changes in the expression of genes for chemokines, cytokines, and their receptors in the mouse spleen. These alterations were evident at both 6 and 24 hours after a single administration. The observed changes in gene expression suggest a broad and rapid immunomodulatory response. The most striking finding was that changes in the mRNA level of the majority of the genes under study were similarly observed after the administration of Gly-Pro, suggesting this minimal fragment plays a crucial role in Selank's immunomodulatory effects. This indicates that Gly-Pro effectively mimics the parent peptide's influence on immune gene regulation, pointing to its importance in Selank's overall pharmacological profile.

Why It Matters

This research significantly advances our understanding of Selank's mechanism of action, particularly its immunomodulating effects at the genetic level. Identifying Gly-Pro as a key pharmacophor for these effects opens new avenues for developing targeted therapies. Given Selank's existing anxiolytic, nootropic, and antiviral properties, understanding its immune modulation could lead to broader clinical applications, potentially in conditions involving immune dysregulation or viral infections. Future research should focus on identifying the specific genes and pathways affected and validating these findings in human trials (Phase I/II) to explore its therapeutic potential.


selank anxiolytic nootropic safety data present
Source: pubmed:21786679 · Ingested 2026-04-03 · Digest: gemini-2.5-flash